CN1053363C - Oral liquid of shengxueyin - Google Patents
Oral liquid of shengxueyin Download PDFInfo
- Publication number
- CN1053363C CN1053363C CN95110240A CN95110240A CN1053363C CN 1053363 C CN1053363 C CN 1053363C CN 95110240 A CN95110240 A CN 95110240A CN 95110240 A CN95110240 A CN 95110240A CN 1053363 C CN1053363 C CN 1053363C
- Authority
- CN
- China
- Prior art keywords
- radix
- oral liquid
- shengxueyin
- present
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007788 liquid Substances 0.000 title description 15
- 210000000265 leukocyte Anatomy 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 16
- 210000002784 stomach Anatomy 0.000 description 13
- 238000002512 chemotherapy Methods 0.000 description 12
- 230000037396 body weight Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 235000013495 cobalt Nutrition 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- 230000000292 leukogenic effect Effects 0.000 description 4
- 241000756943 Codonopsis Species 0.000 description 3
- 241000222336 Ganoderma Species 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- 229910017052 cobalt Inorganic materials 0.000 description 3
- 239000010941 cobalt Substances 0.000 description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XDBMTQVSHNQIFU-UHFFFAOYSA-N 2-(2-ethoxy-2-oxo-1-phenylethyl)-1,3-thiazolidin-3-ium-4-carboxylate Chemical compound C=1C=CC=CC=1C(C(=O)OCC)C1NC(C(O)=O)CS1 XDBMTQVSHNQIFU-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000608867 Leucogenes Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- IWWCATWBROCMCW-UHFFFAOYSA-N batyl alcohol Natural products CCCCCCCCCCCCCCCCCCOC(O)CO IWWCATWBROCMCW-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 108010052008 colla corii asini Proteins 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000388 leucogen effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000003039 myelosuppressive effect Effects 0.000 description 1
- CCHNOBQMQBSRHQ-UHFFFAOYSA-N phosphoric acid;7h-purin-6-amine Chemical compound OP(O)(O)=O.NC1=NC=NC2=C1NC=N2 CCHNOBQMQBSRHQ-UHFFFAOYSA-N 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention belongs to Chinese herbal medicine oral liquid for promoting the growth of leucocytes and preventing bone marrow inhibition. A formula comprises that suberect spatholobus, milkvetch root, glossy privet fruit, ganoderma, tangshen, angelica, epimedium herb, radix glycyrrhiza, radix asparagi, batata, cassia bark, acanthopanax, prepared rhizome of rehmannia and raspberry are purified and sterilized by alcohol, and obtained medicinal liquid is decocted in sterilized water. The present invention has the functions of strengthening physical power, promoting the growth of leucocytes and preventing bone marrow inhibition. After the product is taken, patients can easily complete treatment courses of radiotherapy and chemotherapy, and the present invention is a health-care tonic product which integrates the functions of disease treatment and nutrient supply.
Description
The invention belongs to a kind of leukocyte of promotion growth that has, the Chinese herbal medicine oral liquid of control bone marrow depression function.
At present, 60 cobalt radiotherapies and cyclophosphamide (being called for short CTX) chemotherapy are mainly adopted in the treatment of various malignant tumor.These two kinds of therapeutic modalities all destroy the intravital leukocyte of patient to some extent, produce negative interaction.For making smooth the hitting the target the course of treatment of treatment, most hospitals all adopt the leucogen, batyl alcohol, and adenine phosphate, polyactin, medicines such as Colla Corii Asini slurry prevent and treat bone marrow depression, but effect are all not obvious to promote leukocyte growth in patient's body.
The purpose of this invention is to provide a kind of promotion leukocyte growth, prevent and treat the double Chinese herbal medicine oral liquid of protecting the type of building of myelosuppressive treatment.
Oral liquid of shengxueyin is a kind of Chinese herbal medicine oral liquid, and the weight ratio of its material component is followed successively by:
Caulis Spatholobi 0.15～0.3: the Radix Astragali 0.1～0.2: Fructus Ligustri Lucidi 0.1～0.2:
Ganoderma 0.05～0.1: Radix Codonopsis 0.05～0.1: Radix Angelicae Sinensis 0.05～0.1:
Herba Epimedii 0.01～0.15: Radix Glycyrrhizae 0.1～0.15: Radix Asparagi 0.1～0.15:
Rhizoma Dioscoreae 0.1～0.15: Cortex Cinnamomi 0.05～0.1: Radix Et Caulis Acanthopanacis Senticosi 0.1～0.15:
Radix Rehmanniae Preparata 0.15～0.2: Fructus Rubi 0.1～0.2
Preparation method of the present invention is: above 14 flavor medical herbs are soaked half an hour, decoct then three times, be blended into ethanol after the gained mixed liquor concentrates and purify, make reflow of alcohol after the purification, cooled and filtered, bottling sterilization at last.
The oral liquid of shengxueyin that adopts the said method infusion is a kind of Chinese herbal and crude drugs preparations for the treatment of the health of holding concurrently, because it is soft, be applicable to that the each age group patient takes, particularly to weak and sickly gerontal patient with can not to finish patient's effect of treatment plan to the ability to bear difference of radiotherapy and chemotherapy particularly remarkable.
1993, through the paired observation test that railway hospital in Dalian carries out 1321 side tumor patients, result of the test proved: the patient who takes oral liquid of shengxueyin finishes and radiocurablely reaches 92.9%.In addition, do experiment effect also clearly with mice.
One, CTX is handled the therapeutic effect of mice
Mice is divided into three groups by the body weight stratified random, makes between group the average weight difference basically less than 1.0 grams.Each is organized first day and irritates stomach CTX once by 100mg/kg.d. dosage, and every day is irritated the stomach oral liquid of shengxueyin in beginning in second day, 20 milliliters/kilogram of high dose group, and 10 milliliters/kilogram of low dose group, matched group is irritated the stomach normal saline once a day, successive administration four days.Got tail vein, and looked into total white blood cells in the 6th day.Obtain the leukocyte rate of rise by following formula:
The results are shown in Table 1. leukogenic effect is arranged.High dose group is compared with matched group, and leukocyte raises 27,5%, P value＜0.02, significant difference.
Table 1. couple CTX handles the therapeutic effect of mice
Group mice body weight (gram) leukocyte count
Experiment back before N P value (milliliter/kilogram) experiment (individual/mm)
20 10 20 18.83 11112±3194 ＜0.02
10 10 19.7 18.4 8977±2442
Contrast 10 19.7 18.8 8717 ± 2835
Two, give the therapeutic effect of CTX after the protection of administration in advance again
Mice is divided into three groups (method is the same) by the body weight stratified random.Each is organized and irritates the stomach oral liquid of shengxueyin every day, 20 milliliters/kilogram of high dose group, 10 milliliters/kilogram of low dose group.Matched group is irritated the stomach normal saline.Once a day, successive administration is eight days.The 5th day each group increases irritates stomach CTX once, and dosage is 100mg/kg, and d got tail vein on the 9th day, looked into total white blood cells, calculated leukocyte rate of rise (the same).
The results are shown in Table 2. leukogenic effect is arranged.High dose group is compared with matched group, and leukocyte raises 43.8%, P value＜0.005, difference highly significant.
Give the therapeutic effect of CTX after the table 2. administration in advance protection again
Group mice body weight (gram) leukocyte count
Experiment back before N P value (milliliter/kilogram) experiment (individual/mm)
20 11 19.6 19.5 14327±3761 ＜0.005
10 11 19.8 18.7 12181±3335
Contrast 12 19.5 19.0 9966 ± 2217
Three, CTX is handled the protection effect of mice
Mice is divided into three groups (method is the same) by the body weight stratified random.Each is organized first day and irritates stomach CTX once by 60mg/kg.d. dosage, begins to irritate the stomach oral liquid of shengxueyin in second day.20 milliliters/kilogram of high dose group, 10 milliliters/kilogram of low dose group, matched group is irritated the stomach normal saline.Once a day, successive administration is three days.Reach administration before the administration and get tail vein after three days, look into total white blood cells.Obtain the protection effect by following formula:
Though the results are shown in Table leukocyte counts of 3. each group, compare all and descend after the administration with before the administration, grand down more obvious of matched group, have only administration preceding 65.1%, P value＜0.05.High dose group then is 86.6% before the administration, and P value＞0.05 presents the protection effect after administration is described.
Table 3. couple CTX handles the protection effect of mice
Group leukocyte count (individual/mm3) (gram)
Administration is after three days before the administration of N protection effect P value (milliliter/kilogram)
8018±2112 6945±2926
20 11 1.33 ＞0.05
(100) (86.6)
9307±2829 6390±1393
10 11 1.05
1100 168.61
10352±4228 6736±2303
Contrast 11＞0.05
(100) (65.1)
Four, 60 cobalts are handled the therapeutic effect of mice
Mice is divided into three groups (method is the same) by the body weight stratified random.Each organizes first day by S=400cm2, and skin is apart from 75cm, the rectangular once irradiating 60 cobalt rays of accumulated dose 100Cry.Began to irritate the stomach oral liquid of shengxueyin in second day, 20 milliliters/kilogram of high dose group, 10 milliliters/kilogram of low dose group.Matched group is irritated the stomach normal saline.Day once, successive administration six days.Got tail vein, and looked into total white blood cells in the 8th day.Calculate leukocyte rate of rise (method is the same).
It is comparatively obvious to the results are shown in Table 4. leukogenic effects.High dose group is compared with matched group, and leukocyte raises 53.8%, P value＜0.005, difference highly significant.
Table 4. pair 60 cobalts are handled the therapeutic effect of mice
Group mice body weight (gram) leukocyte count
Experiment back before N P value (milliliter/kilogram) experiment (individual/mm3)
20 10 19.7 20.1 10505±2601 ＜0.005
10 10 19.7 21.55 8505±3690
Contrast 10 19.85 21.7 6830 ± 2193
Five, shine 60 cobaltic therapeutic effect again after the protection of administration in advance
Mice is divided into two groups (method is the same) by the body weight stratified random.Experimental group is irritated 10 milliliters/kilogram of stomach oral liquid of shengxueyin every day, and matched group is irritated the stomach normal saline.Once a day, successive administration is eight days.Each group press S=400cm in the 4th day, and skin is apart from 75cm, accumulated dose 100Cry, rectangular once irradiating cobalt ray.Get tail vein on the 9th day, and looked into total white blood cells, calculate leukocyte rate of rise (method is the same).
The results are shown in Table 5, leukogenic effect is comparatively obvious.Experimental group is compared with matched group, and leukocyte raises 48%, P value＜0.005, difference highly significant.
Shine 60 cobaltic therapeutic effect again after the table 5. administration in advance protection
Group mice body weight (gram) leukocyte count
Experiment back before N P value (milliliter/kilogram) experiment (individual/mm)
10 11 19.8 22.6 10468±2921 ＜0.005
Contrast 12 20 23.8 7070 ± 1797
Oral liquid of shengxueyin of the present invention is achieved by the following technical solution:
1. the present invention's prescription as follows: (unit gram)
Caulis Spatholobi 30; The Radix Astragali 20; Fructus Ligustri Lucidi 20; Ganoderma 10; Radix Codonopsis 10;
Radix Angelicae Sinensis 10; Herba Epimedii 15; Radix Glycyrrhizae 15; Radix Asparagi 15; Rhizoma Dioscoreae 15;
Cortex Cinnamomi 10; Radix Et Caulis Acanthopanacis Senticosi 15; Radix Rehmanniae Preparata 20; Fructus Rubi 20.
Above-mentioned 14 flavor medicines are put into jar add after 1000 gram sterilized water soak half an hour, divides three decoction, decocting time is identical, puts into sterilized water 500 during second and third time decoction more respectively and restrains.Three decoction gained medicinal liquid 500 grams that are concentrated into admixed together, the ethanol that adds 1000 grams 97% carries out purification processes, and vaporized alcohol is refluxed, and cooled and stored was used filter paper filtering after 48 hours.Bottle at last and use γShe Xianmiejun.
2. also prescription in the following manner of the present invention: (unit gram) Caulis Spatholobi 15; The Radix Astragali 10; Fructus Ligustri Lucidi 10; Ganoderma 5; Radix Codonopsis 5; Radix Angelicae Sinensis 5; Herba Epimedii 10; Radix Glycyrrhizae 10; Radix Asparagi 10; Rhizoma Dioscoreae 10; Cortex Cinnamomi 5; Radix Et Caulis Acanthopanacis Senticosi 10; Radix Rehmanniae Preparata 15; Fructus Rubi 10.Concrete preparation method is with 1.
Claims (1)
1. an oral liquid of shengxueyin is to promote the leukocyte growth, prevents and treats myelosuppressive Chinese herbal medicine oral liquid, it is characterized in that the weight ratio that contains material component is followed successively by:
Caulis Spatholobi 0.15～0.3: the Radix Astragali 0.1～0.2: Fructus Ligustri Lucidi 0.1～0.2:
Ganoderma 0.05～0.1: Radix Codonopsis 0.05～0.1: Radix Angelicae Sinensis 0.05～0.1:
Herba Epimedii 0.01～0.15: Radix Glycyrrhizae 0.1～0.15: Radix Asparagi 0.1～0.15:
Rhizoma Dioscoreae 0.1～0.15: Cortex Cinnamomi 0.05～0.1: Radix Et Caulis Acanthopanacis Senticosi 0.1～0.15:
Radix Rehmanniae Preparata 0.15～0.2: Fructus Rubi 0.1～0.2
Preparation technology is: above-mentioned 14 flavor medical herbs are soaked half an hour, decoct then three times, be blended into ethanol after the gained mixed liquor concentrates and purify, make reflow of alcohol after the purification, cooled and filtered, last bottled sterilization.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95110240A CN1053363C (en) | 1995-05-16 | 1995-05-16 | Oral liquid of shengxueyin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN95110240A CN1053363C (en) | 1995-05-16 | 1995-05-16 | Oral liquid of shengxueyin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1135904A CN1135904A (en) | 1996-11-20 |
| CN1053363C true CN1053363C (en) | 2000-06-14 |
Family
ID=5077644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN95110240A Expired - Fee Related CN1053363C (en) | 1995-05-16 | 1995-05-16 | Oral liquid of shengxueyin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1053363C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1943661B (en) * | 2005-10-08 | 2010-11-10 | 周小明 | A Chinese traditional medicinal composition and its preparation method |
| PT2341918T (en) * | 2008-09-25 | 2018-06-01 | Life Biotech Medical Res Ltd | Herbal formulations |
| CN104306698B (en) * | 2014-09-30 | 2017-05-17 | 哈尔滨乐泰药业有限公司 | Traditional Chinese medicine composition for enhancing human body immunity, as well as preparation method and application thereof |
| CN104491267A (en) * | 2015-01-08 | 2015-04-08 | 李宏 | Traditional Chinese medicine composition for alleviating bone marrow inhibition effect caused by chemotherapy and preparation method thereof |
| CN105726776A (en) * | 2016-03-03 | 2016-07-06 | 郑州大学 | Traditional Chinese medicine for alleviating bone marrow inhibition reaction caused by paclitaxel chemotherapy |
-
1995
- 1995-05-16 CN CN95110240A patent/CN1053363C/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| 上海中医药杂志 1985.1.1 中药为主治疗急性症再生障碍贫血25例疗效观察 * |
| 上海中医药杂志 1985.1.1 中药为主治疗急性症再生障碍贫血25例疗效观察;中西医结合杂志(中) 1988.8.1 活血化瘀中药抗癌药治疗急性白血病近期疗效观察，邓有安等 * |
| 中西医结合杂志(中) 1988.8.1 活血化瘀中药抗癌药治疗急性白血病近期疗效观察，邓有安等 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1135904A (en) | 1996-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1151800C (en) | Medicine for curing diabetic peripheral neuropathy | |
| CN1183919C (en) | Cancer treating medical composition | |
| CN1053363C (en) | Oral liquid of shengxueyin | |
| CN1124156C (en) | Chinese-medicinal pills for treating rheumatism and preparing process thereof | |
| CN1054773C (en) | Chinese patent drug "Bizhengning" for treatment of arthralgia-syndrome | |
| CN1057924C (en) | Drug preparation for curing viral and many kinds of myocarditis, low fever and hypokalemia | |
| CN1943689A (en) | A Chinese traditional medicinal composition for treatment of wind-heat type common cold and its preparation method | |
| CN110934924A (en) | Traditional Chinese medicine bone marrow hematogenesis composition and application thereof | |
| CN1060657C (en) | Nourishing medicine for preventing and curing toxic and side effect after tumor radiotherapy and chemotherapy and preparation method | |
| CN1839944A (en) | Granular composition for reducing blood fat and process for producing the same | |
| CN1102104A (en) | Adhesive plaster capable of detoxicating and resolving a mass | |
| CN1163251C (en) | Weishukang for treating gastrosis | |
| CN1290545C (en) | Medicine for curing coronary heart disease | |
| CN1481870A (en) | Compound traditional Chinese medicine preparation for treating intractable chronic constipation and preparation method thereof | |
| CN1136939A (en) | Chinese drugs for curing hepatitis B | |
| CN1377672A (en) | Rheumatic pain killing preparation | |
| CN1081042C (en) | Traditional Chinese medicinal composition for stopping drug taking and preparation process thereof | |
| CN1931300A (en) | Externally applied medicine for treating women's dysmenorrhea | |
| CN1216623C (en) | Blood pressure reducing and stabiliaing Chinese medicine and its prepn | |
| CN1083725C (en) | Cordyceps medicinal composition and its preparing method | |
| CN1190229C (en) | Medicine for curing hepatitis B | |
| CN1062480C (en) | Oral liquor for curing urethritis | |
| CN1127968C (en) | Oral powder medicine Xiaobaisan for treating leukotrichia and its preparation method | |
| CN1140281C (en) | Yiyuansan powder as one orally taken medicine for treating liver cancer and its preparation | |
| CN1042495C (en) | Medicine for benefitting Qi, removing cancer and raising leucocyte and its prepn. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |